Sunday, February 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Nations Pay Wildly Different Prices For Vaccines

In an ideal world, the price of a vial of vaccine would be consistent across the globe.

But at this stage of the vaccine rollout, it’s difficult to find out basic facts – like, how much a vial costs. Companies are keeping exact prices a secret.

To bring more transparency, UNICEF has compiled a chart of how much countries and nonprofit groups are paying for doses, drawing from local news reports, reporting by Reuters and documents obtained from various sources.

There’s a significant range in price because some vaccines are more expensive to produce than others.

But even for the very same vaccine – the AstraZeneca vaccine touted as one of the most affordable in the world – there are notable differences.

Source: NPR

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

2027 Medicare Advantage & Part D Advance Notice

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us

Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...

Read more

Join Our Newsletter!